Lamivudine
When ATH:
J05AF05
Characteristic.
White or off-white crystalline powder, solubility in water at 20 °C примерно 70 mg / ml. Molecular weight 229,3.
Pharmacological action.
Antiviral, inhibiting HIV reverse transcriptase.
Application.
HIV infection in adults and children.
Contraindications.
Hypersensitivity.
Restrictions apply.
Renal and / or hepatic insufficiency, pancreatitis (incl. history), peripheral neuropathy (incl. history), pregnancy, lactation, infancy up 3 Months (data on efficacy and safety are absent).
Pregnancy and breast-feeding.
Possible only, when the intended benefits to the mother outweighs the potential risk to the fetus and child.
Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)
Side effects.
Headache, dizziness, weakness, insomnia, gipotimiya, neuropathy, cough, flu-like symptoms, anorexia, nausea, diarrhea, vomiting, epigastric pain, necrotizing pancreatitis (possible death), myalgia, arthralgia, leukopenia, anemia, fever, Sweating, alopecia, allergic reactions.
Cooperation.
Increases Cmax zidovudine 39 ± 62%. Trimethoprim and sulfamethoxazole increase in the AUC of lamivudine 44 ± 23%, reduce its total Cl on 29 ± 13% и почечный Cl на 30 ± 36%.
Overdose.
Treatment: symptomatic, gastric lavage, appointment of activated carbon, diurez, monitoring vital functions.
Dosing and Administration.
Inside. Adults and adolescents (12-16 Years): 150 mg 2 once a day, birth weight less than 50 kg - 2 mg / kg 2 once a day; children (from 3 Months before 12 years) calculated 4 mg / kg 2 once a day, the maximum daily dose 300 mg. Appointed only in combination with zidovudine.
Precautions.
Should suspend treatment if deterioration in liver function tests, Fatty, progressive hepatomegaly or lactic acidosis of unknown aetiology.
Cooperation
| Active substance | Description of interaction |
| Abacavir | FKV. Slows down and reduces Cmax и AUC (on 35 and 15% respectively); the combined appointment dose adjustment is not required. |
| Trimethoprim | FKV. Increases concentration in the tissues. |
